Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 13,596 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed Not applicable Interventional

Acupuncture in Treating Hot Flashes in Women With Breast Cancer

NCT00081965
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
acupuncture therapy, hot flashes attenuation, management of therapy complications
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 27, 2026, 10:01 PM EDT
Terminated Not applicable Interventional

Cardiac Rehabilitation to Improve Breast Cancer Outcomes

NCT05867667
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Diseases
Interventions
Cardiac Rehab
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 27, 2026, 10:01 PM EDT
Recruiting No phase listed Observational

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

NCT07148245
View directory record Official record
Conditions
Cutaneous Melanoma, Cutaneous Melanoma, Stage III, Cutaneous Melanoma by AJCC V7 Stage, Cutaneous Melanoma, Stage IV
Interventions
Blood Sample, Health Related Quality of Life Questionnaires (HRQoL), Medical Chart Review
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 1 Interventional

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

NCT02897375
View directory record Official record
Conditions
Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
Interventions
Carboplatin, Cisplatin, Palbociclib
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

NCT06126575
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Elacestrant dihydrochloride
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Yucaipa, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 27, 2026, 10:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer With Bone Involvement, Bone Metastases in Subjects With Advanced Breast Cancer, ER-Positive HER2-Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Hormone-sensitive Metastatic Breast Cancer, Hormone-Sensitive Breast Cancer
Interventions
RYZ101, Standard of Care Endocrine Therapy
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
Not listed
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting

NCT03034694
View directory record Official record
Conditions
Cellulitis
Interventions
teledermatology consult, Routine Care
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 27, 2026, 10:01 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Tolerability of a Fractional Ablative Erbium Laser for Axillary Scarring for Hidradenitis Suppurativa Patients

NCT05470322
View directory record Official record
Conditions
Hidradenitis Suppurativa, Scarring
Interventions
Er: YAG laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

NCT01227551
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Coxsackievirus A21 (CVA21)
Biological
Lead sponsor
Viralytics
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Miami Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Repeat Insult Patch Test to Evaluate Personal Lubricants

NCT02737631
View directory record Official record
Conditions
Erythema, Edema
Interventions
"Chameleon" Personal Lubricant
Device
Lead sponsor
Church & Dwight Company, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
222 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 27, 2026, 10:01 PM EDT
Active, not recruiting Not applicable Interventional

Ultrahypofractionation and Normal Tissue Toxicity

NCT05912231
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Breast Cancer Stage II, Breast Cancer Stage III, Myocardial Fibrosis
Interventions
Accelerated Proton Beam Radiation Therapy (PBT), Accelerated Photon Radiation Therapy (XRT)
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Not applicable Interventional Results available

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

NCT00791557
View directory record Official record
Conditions
Pyoderma Gangrenosum, Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions
Infliximab
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

NCT03617328
View directory record Official record
Conditions
Melanoma
Interventions
6MHP, Montanide ISA-51, polyICLC, CDX-1127
Biological · Drug
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 27, 2026, 10:01 PM EDT
Completed No phase listed Observational

An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer

NCT00291122
View directory record Official record
Conditions
Breast Cancer
Interventions
celecoxib 400 mg BID
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT03533751
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Etokimab, Placebo
Biological · Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 27, 2026, 10:01 PM EDT
Terminated No phase listed Observational

Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

NCT04932031
View directory record Official record
Conditions
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
Interventions
Not listed
Lead sponsor
Sapere Bio
Industry
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 27, 2026, 10:01 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

NCT02147951
View directory record Official record
Conditions
Unresected Stage IIIb to IVM1c Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy

NCT00886795
View directory record Official record
Conditions
Urticaria
Interventions
abatacept (Orencia ®)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines

NCT05032157
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded), Placebo, LOU064 (open-label)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

NCT02730819
View directory record Official record
Conditions
Melasma
Interventions
Illuminate Cream
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 27, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

NCT00817362
View directory record Official record
Conditions
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
Interventions
IPI-504, Trastuzumab
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Palm Springs, California • Boca Raton, Florida • Davie, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 27, 2026, 10:01 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Onvansertib + Paclitaxel In TNBC

NCT05383196
View directory record Official record
Conditions
Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions
Onvansertib, Paclitaxel
Drug
Lead sponsor
Antonio Giordano, MD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 27, 2026, 10:01 PM EDT
Completed Not applicable Interventional

CBPR - BRCA Genetic Testing Among Orthodox Jews

NCT03624088
View directory record Official record
Conditions
Breast Cancer
Interventions
RealRisks
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
25 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 27, 2026, 10:01 PM EDT
Recruiting Phase 1 Interventional

IL-17 Blockade to Decrease irAEs (REPLAY)

NCT07237594
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Secukinumab Injection
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 27, 2026, 10:01 PM EDT